Zobrazeno 1 - 10
of 81
pro vyhledávání: '"Gopalan Sethuraman"'
Autor:
Catherine Reed, Mark Belger, Grazia Dell’Agnello, Kristin Kahle-Wrobleski, Gopalan Sethuraman, Ann Hake, Joel Raskin, David Henley
Publikováno v:
Alzheimer’s Research & Therapy, Vol 10, Iss 1, Pp 1-11 (2018)
Abstract Background Comparison of disease progression between placebo-group patients from randomised controlled trials (RCTs) and real-world patients can aid in assessing the generalisability of RCT outcomes. This analysis compared outcomes between c
Externí odkaz:
https://doaj.org/article/bec4068ab80e44c89ea1aa39626780f0
Autor:
Malik, Imtiaz A., Gopalan, Sethuraman
Publikováno v:
European Journal of Epidemiology, 2003 Jan 01. 18(8), 817-822.
Externí odkaz:
https://www.jstor.org/stable/3582931
Autor:
Michael S, Rafii, Reisa A, Sperling, Michael C, Donohue, Jin, Zhou, Claire, Roberts, Michael C, Irizarry, Shobha, Dhadda, Gopalan, Sethuraman, Lynn D, Kramer, Chad J, Swanson, David, Li, Stephen, Krause, Robert A, Rissman, Sarah, Walter, Rema, Raman, Keith A, Johnson, Paul S, Aisen
Publikováno v:
Alzheimer's & Dementia. 19:1227-1233
The Alzheimer's disease (AD) continuum begins with a long asymptomatic or preclinical stage, during which amyloid beta (Aβ) is accumulating for more than a decade prior to widespread cortical tauopathy, neurodegeneration, and manifestation of clinic
Autor:
Joshua Grill, Tyler Berkness, Maria C. Carrillo, Heather M. Snyder, Paul Aisen, Reisa A. Sperling, Ronald C. Petersen, Neelum T. Aggarwal, Karen L. Bell, Jeffrey M. Burns, Michael C. Donohue, Hiroko H Dodge, Mark A. Espeland, Daniel L. Gillen, David S. Geldmacher, Judith L Heidebrink, Gregory A Jicha, John M. Olichney, Michael S Rafii, Dorene M. Rentz, Stephen P. Salloway, Gopalan Sethuraman, Amanda G Smith, Rema Raman
Publikováno v:
Alzheimer's & Dementia. 18
Autor:
Jin Zhou, Michael C Irizarry, Lynn D Kramer, Chad J Swanson, Claire Roberts, Shobha Dhadda, David JianJun Li, Martin Rabe, Stephen Krause, Rema Raman, Michael C Donohue, Gopalan Sethuraman, Keith A. Johnson, Reisa A. Sperling, Paul S Aisen
Publikováno v:
Alzheimer's & Dementia. 17
Autor:
Paul S. Aisen, Shobha Dhadda, Chad J. Swanson, Michael C. Irizarry, David JianJun Li, Michael C. Donohue, Gopalan Sethuraman, Keith A. Johnson, Reisa A. Sperling, Jin Zhou, Stephen Krause, Martin Rabe, Rema Raman, Lynn D. Kramer
Publikováno v:
Alzheimer's & Dementia. 16
Autor:
Gopalan Sethuraman, Oliver Langford, Reisa A. Sperling, Michael C. Donohue, Paul S. Aisen, Wesley K. Thompson, Rema Raman, Philip S. Insel, Wenyi Lin
Publikováno v:
Alzheimer's & Dementia. 16
Semagacestat, a γ-secretase inhibitor, demonstrated an unfavorable risk–benefit profile in a Phase 3 study of patients with Alzheimer’s disease (IDENTITY trials), and clinical development was halted. To assist in future development of γ-secreta
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::617aab97728530126cae39ab06d46174
Autor:
Gopalan Sethuraman, Guoqiao Wang, Jason Hassenstab, Randall J. Bateman, Scott M. Berry, Chengjie Xiong, Matteo Vestrucci, Eric McDade, Paul Delmar, Melanie Quintana
Publikováno v:
Statistics in Medicine. 37:3047-3055
Clinical trial outcomes for Alzheimer’s disease are typically analyzed by using the mixed model for repeated measures (MMRM) or similar models that compare an efficacy scale change from baseline between treatment arms with or without participants
Autor:
Ann Marie Hake, Joel Raskin, Grazia Dell'Agnello, Mark Belger, Kristin Kahle-Wrobleski, Gopalan Sethuraman, Catherine Reed, David Henley
Publikováno v:
Alzheimer’s Research & Therapy, Vol 10, Iss 1, Pp 1-11 (2018)
Alzheimer's Research & Therapy
Alzheimer's Research & Therapy
Comparison of disease progression between placebo-group patients from randomised controlled trials (RCTs) and real-world patients can aid in assessing the generalisability of RCT outcomes. This analysis compared outcomes between community-dwelling pa